|
1. Economic disaster followed by a revival in share prices
2. Dealmaking reaches fever pitch at year's end
3. Big Pharma upends its R&D empires
Showing posts with label biotechnology. Show all posts
Showing posts with label biotechnology. Show all posts
| The top bioscience news stories around the state thanks to the Flinn Foundation... Follow Biozona News via: Twitter | Google News | RSS | Evernote. For related info--and new connections--join the AZBio LinkedIn group. | ||||
 |
Abraxis, schools start nonprofit for better health care
02/26/2010 | Phoenix Business Journal | Angela Gonzales
Arizona State University, the University of Arizona and the founder of Abraxis BioScience Inc. are in early discussions to create a nonprofit organization to improve health outcomes and the way patient care is delivered. The goal of the Health Transformation Institute is to link the three separate worlds of scientific discovery, health care delivery and reimbursement.
St. Joe's set for pediatric heart transplants
02/26/2010 | Phoenix Business Journal | Angela Gonzales
St. Joseph's Hospital and Medical Center is launching the Valley's first pediatric heart transplant program. In Arizona, 10 to 20 children become eligible for the surgery each year, Nigro said. They have had to travel to Tucson's University Medical Center or other states to receive heart transplants because no local doctors were qualified to perform the procedure.
Medical Clinical Trials Face Obstacles
02/26/2010 | KPHO.com | Donna Rossi
In collaboration with the Virginia G. Piper Cancer Center at Scottsdale Healthcare, the Translational Genomics Research Institute has about 35 clinical trials under way. New drugs are constantly in development. But some of the clinical trials to test these new drugs could be at risk if more cancer patients don't get involved in the studies.
Bioscience students network with top AZ companies
02/25/2010 | Daily Wildcat | Luke Money
UA bioscience students met with some of Arizona's largest bioindustry companies during the Second Annual UA Student/Bioindustry Networking Event on Wednesday. Ten private companies attended the event. They included Genomics USA, Ventana Medical Systems, and W.L. Gore.
New Science to Bolster FDA Drug Approval (Notes work by C-Path)
02/24/2010 | ScienceInsider | Jocelyn Kaiser
The National Institutes of Health and the U.S. Food and Drug Administration today announced a new initiative, including a grants program funded at up to $6.75 million over 3 years, to support regulatory science, the tools and standards used to evaluate new drugs and devices. The initiative comes in addition to a proposed $25 million for regulatory science in FDA's 2011 budget for nanotechnology and other areas.
Teasing Vaccines From Tobacco (Notes work by ASU, VAXX)
02/24/2010 | Wall Street Journal | Gautam Naik
The U.S. Department of Defense, caught off guard by the swift spread of the H1N1 flu virus last year and delays in producing a vaccine, is backing an unusual plan to use tobacco plants to make the vaccine. Flu vaccines are typically grown in chicken eggs. Although the technique is slow and expensive, vaccine makers have done little to improve on this reliable method for more than 60 years. The urgent need for a better way became apparent last year.
Intel, partners to give $3.5 billion to tech startups
02/24/2010 | Arizona Republic | Andrew Johnson
Intel Corp.'s plans to direct $3.5 billion of investments into U.S. technology companies could help cash-strapped startups in Arizona, where venture-capital activity is lagging. The Santa Clara, Calif.-based semiconductor giant said Tuesday that its venture-capital arm, Intel Capital, was forming a $200 million fund to focus on domestic companies developing "clean" technology, information technology and biotech.
© 2002-2010 Flinn Foundation. All Rights Reserved.
© 2002-2010 Flinn Foundation. All Rights Reserved.
01/20/2010 | Bio-IT World | John Russell
Turning FDA's Critical Path Initiative (CPI) into practical tools to accelerate drug discovery and development has had its challenges. But that hasn't deterred Ray Woosley, CEO of the C-PATH Institute, whose sole mission is to foster private-public cooperation to fulfill CPI's grand vision. Woosley is a glass-half-full realist and C-PATH is starting to justify his steady confidence.
Sanofi-aventis raises a glass
01/20/2010 | The Explorer | Dave Perry
Flutes of champagne were lifted skyward last Wednesday morning in Oro Valley, where Sanofi-aventis associates from across the nation and beyond celebrated the opening of the company's 110,350-square-foot Tucson Research Center.
T-Gen-Van Andel deal spurs new contract
01/17/2010 | Arizona Republic | Ken Alltucker
After months of review, the Arizona Biomedical Research Commission last week signed off on a new contract that ensures continued funding of Phoenix-based Translational Genomics Research Institute. The commission sought the new contract with TGen to protect Arizona's interests in the wake of TGen's alliance with Grand Rapids, Mich.-based Van Andel Institute.
Sanofi-Aventis unveils state-of-art research facility
01/15/2010 | Inside Tucson Business | Joe Pangburn
Sanofi-Aventis, one of the world's largest pharmaceutical companies, has a cure for needed research space: Last week, it showed off its expanded Tucson Research Center, a 110,350 square-foot, state-of-the-art facility in Oro Valley's Innovation Park.
Infrastructure projects help stimulate economy, pave way for growth
01/15/2010 | Phoenix Business Journal
According to Arizona's Bioscience Roadmap, commissioned and coordinated by the Flinn Foundation, the state needs to focus on four strategies to develop a strong bioscience hub. Here are those strategies and how the greater Phoenix area has fared since the October report.
ASU, Mayo partner to fight diseases related to obesity
01/15/2010 | Phoenix Business Journal | Angela Gonzales
Arizona State University and Mayo Clinic in Scottsdale are partnering to combat diseases associated with obesity, Type II diabetes, cardiovascular disease, stroke and other expensive conditions. The two organizations have created the ASU/Mayo Center for Metabolic and Vascular Biology, which is recruiting 50 doctors and scientists.
Several Valley biotech firms are marketing health-related products
01/15/2010 | Phoenix Business Journal | Angela Gonzales
The theme for biotech startups in Arizona this year is shaping up to be "health and fitness." Local entrepreneurs are working on everything from vibrating fitness gear to breath analyzer technology used to determine how effectively a person burns fat during a workout.
5 Questions about Arizona Bioscience: Robert Green, AZBio President and CEO
01/15/2010 | Phoenix Business Journal
How has the state's bioscience community fared during the recession? Looking into your crystal ball, what is the outlook for access to financing in 2010 for biotech startups and spinouts? Has AZBio made any adjustments based on the current economic situation? Coming from Tucson, how will you help Phoenix and Tucson bioscience entities collaborate this year? What is AZBio's focus this year?
UA researchers part of $44B biofuel program
01/13/2010 | Phoenix Business Journal | Angela Gonzales
Several University of Arizona researchers are part of a consortium that received a $44 million U.S. Department of Energy grant to bring algae-based biofuels to market. The federal agency announced on Wednesday that nearly $80 million under the American Recovery and Reinvestment Act will be awarded to the National Advanced Biofuels Consortium and the National Alliance for Advanced Biofuels and Bioproducts. UA is a founding member of the latter.
AZ Economic Driver Biosciences Could Stall After 2010
01/13/2010 | Tech News Arizona | Alan Fischer
Arizona's bioscience sector continued to grow despite a hard-hitting global recession and cutbacks in supporting state funding, according to an industry update released this week throughout the state and on Jan. 12 at the Flinn Foundation in Phoenix.
AZ biosciences buck recession as jobs increase
01/13/2010 | Arizona Daily Star | David Wincher
Arizona's biosciences sector made notable gains in 2008 and 2009 despite the recession and its lingering effects, according to a report issued Tuesday. But the state saw its federal medical research grants fall 10 percent, and venture capital remained scarce, says an annual update on the state's 10-year biosciences development plan.
Bioscience industry grows despite budget woes
01/13/2010 | Arizona Republic | Ken Alltucker
Arizona's push to grow the bioscience industry has paid off over the past two years with rapid job growth and new companies despite the difficult economy, a new report says. Although Arizona has made progress on most goals outlined in the annual report by Ohio-based Battelle Technology Partnership Practice, the state's budget woes and lack of early-stage investment in startup companies are challenges that could slow bioscience growth and the high-wage jobs the industry delivers.
Biosciences growth could slow amid budget cuts
01/12/2010 | Phoenix Business Journal | Angela Gonzales
While Arizona's bioscience industry continues its rapid growth in high-paying jobs and firms, a national consultant warns that 2010 may not look so rosy if state budget cuts impact Science Foundation Arizona and state universities' research efforts.
Bioscience makes progress in bad economy
01/12/2010 | East Valley Tribune | Ed Taylor
Despite declining economic conditions, Arizona's bioscience sector made major progress in 2009, according to the authors of the state's plan for growing the industry. "We have put bioscience on the map," said Martin Shultz, chairman of the Arizona's Bioscience Roadmap Steering Committee, in a briefing for reporters Tuesday on the seventh year since publication of the roadmap.
Heart-monitor company to open Phoenix office
01/12/2010 | Arizona Republic | Ken Alltucker
A Pennsylvania company that makes wireless heart monitors has established a new office in Phoenix. Conshohocken, Pa.-based CardioNet said the new Phoenix office, located at 2750 S. 18th Place, will initially employ 20 with plans to grow up to 50 positions based on the company's growth.
Better than a Band-Aid
01/10/2010 | Arizona Daily Sun | Joe Ferguson
A new company at the Flagstaff business incubator is currently testing a biopolymer that could replace stitches and the use of gauze when treating a deep cut or similar wound. The material, known as Elastatropin, might help wounds heal faster and reduce the amount of scarring, said Protein Genomics CEO Burt Ensley.
The movie Old School was on TV a few nights ago. I Always found it to be funny, but never noticed the following scene, in which Will Ferrell is questioned on the subject of Biotechnology...
I am not quite sure anything he is saying makes sense, however perhaps the AZ BioIndustry could learn a thing or two...
Another semester is almost over for me. I have just two more semesters to go before I obtain my bachelors degree in Molecular Bioscience + Biotechnology from Arizona State University.
I am still on an F1 student visa, which has several drawbacks, especially in regards to limiting me to work on campus. I have applied for a green card, however, that may take several years of waiting.
I have been somewhat bored, as I have been out of the lab for the last few months, since my summer internship ended at SunHealth research institute.
About a month ago I was offered an internship position in the immunochemistry department of a global firm that recently opened a new facility in Arizona. It looked very promising, and i had my hopes up, and was eager to start this great opportunity. Unfortunately four weeks later and I am still waiting for them to issue me the application paperwork to fill out. They have also been unresponsive to my emails and phone calls. Once again I have been let down. I believe it to be most unprofessional to behave in this manner. If the position is no longer available, or something else is preventing the hiring, then they should at least have the decency to let me know, so i could then look for something else. To be honest its very frustrating!!!!
Today I had an interview for another internship, this time with the Biodesign Center for Biolectronics and Biosensors. This is a field I am not too familiar with but, sounds very interesting none the less. Drug development and medical technology is just one side of biotechnology. The interview was somewhat longer than I had anticipated, but its always exciting for me to be inside the Biodesign facility. Whether or not I will get the job, at least I will know by Monday.
My last final exam will be next week and then it's winter break. At this rate it looks like i will still have nothing much to do, although I have enrolled in a winter session medical anthropology class and will also be volunteering at Phoenix Children's Hospital.
As I mentioned earlier things are just frustrating. I need a green card and a job. For now I will just keep trying, and I hope something will crop up eventually. I am just itching to get back into a lab and work on something worthwhile. So if anyone is listening....my resume is still up here.
PS the photo is of me (on the far left), at ST3 Entertainments Taboo Tuesdays @ upper Deck
[Source: The Arizona Republic] - InNexus Biotechnology, a drug development company, is moving to Chandler from its location at the Mayo Clinic in Scottsdale.
It will share a building with the future Innovations Technology Incubator at 149 S. 79th St. near Chandler Boulevard and McClintock Drive.
InNexus CEO Jeff Morhet expects to move in part or completely next year.The Chandler site, an Intel structure until five years ago, is 130,000 square feet. The incubator will occupy 40,000, and InNexus will have 20,000, Morhet said.
[SOURCE: Fierce Biotech] This month three Canaccord Adams analysts--Adam Cutler, George Farmer and Ritu Baral (bios and photos)--weigh in on five developers that are facing pivotal events. A timely regulatory approval would mean a lot for one of these companies, another is pushing a new cancer therapy into crucial late-stage trials and a third is fishing for a potential partnership that could make a big difference as it advances three programs in the clinic. A well-timed NDA filing could set the stage for another pact while our fifth company faces a near-term decision from the FDA and some big decisions on a possible partner. Featured in this issue of On the Radar are Cadence Pharmaceuticals, Micromet, Momenta Pharmaceuticals, Pharmasset, and Protalix BioTherapeutics.
Read more @ Fierce Biotech
A Los Angeles-based biotechnology company on Wednesday unveiled a new $70 million Phoenix manufacturing site that will create up to 200 technology jobs.Full Story @ AZCentral
Complete Genomics publishes in Science on low-cost sequencing of 3 human genomes
MOUNTAIN VIEW, Calif. - Nov. 5, 2009 - Complete Genomics, a third-generation human genome sequencing company, today announced publication of a report in the journal Science describing its proprietary DNA sequencing platform, including analysis of sequence data from three complete human genomes. The consumables cost for these three genomes sequenced on the proof-of-principle genomic DNA nanoarrays ranged from $8,005 for 87x coverage to $1,726 for 45x coverage for the samples described in this report.
[Source: The Arizona Republic, Ken Alltucker] - W.L. Gore & Associates will seek Phoenix city approval for up to $30 million in bonds to help finance the medical-product maker's ambitious expansion in north Phoenix.
The bonds would help build a $100 million project anchored by two 100,000-square-foot manufacturing buildings that would support the company's growing medical business. The project would create 1,800 construction jobs over the next two years and 500 permanent jobs as the new site opens, according to documents the company filed with the city's Industrial Development Authority.
The Delaware-based company's Arizona base remains in Flagstaff, where it employs more than 1,500. But the company wants to expand in Phoenix as well, to tap the city's workforce and proximity to a major airport.
For more information: W.L. Gore & Associates plans expansion in Phoenix
The 2009 Biotech Graveyard - FierceBiotech
Last year National Venture Capital Association President Mark Heesen predicted that the coming financial crisis would make or break many small developers. The strong would survive, and the weak would not have what it took to raise cash during the credit crunch. Below is that unfortunate bunch; 16 notable companies that didn't have the money, expertise or programs to live to see another day.
Subscribe to:
Posts (Atom)